The primary objectives of this study are to evaluate the efficacy and safety of 2 SC dosing tiers of ustekinumab in the treatment of adolescent subjects 12 to 18 years of age with moderate to severe chronic plaque psoriasis
Data and Resources
- A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type Psoriasisjson
The primary objectives of this study are to evaluate the efficacy and safety...
|Release Date|| |
License Not Specified
|Public Access Level|| |